Ispire Technology (ISPR) FY2026 10-K: $20.7M Credit Losses vs $12.3M Gross Profit
Listen to this report
Operating cash outflow fell from $7.37M to $0.57M. The net loss stayed above $33M. The gap between those two facts is $20.7M of customers who did not pay.
RoboSystems initiating coverage · Vaping hardware · Source filing: FY2026 Form 10-K for the year ended June 30, 2026, filed September 15, 2026 (accession 0001213900-26-100146, CIK 0001948455). All figures verified directly from the filing's XBRL via RoboSystems and xbrlkit unless attributed otherwise. Not investment advice. No price target.
1. The Hook
Ispire Technology $ISPR spent FY2026 charging $20.7M of credit losses against customers who owe it money. Its entire gross profit for the year was $12.3M. The bad debt was 168% of the gross profit it was booked against.
That is not a one-year accident. FY2025's credit loss expense was $22.0M against $22.6M of gross profit. Over two years Ispire has recognized $42.8M of credit losses on $34.9M of cumulative gross profit. The company has now reserved or written off more than everything it earned above cost across two full fiscal years.
This matters because of a number that looks like good news. Operating cash outflow collapsed from $7.37M in FY2025 to $569K in FY2026, essentially breakeven, while the net loss stayed at $33.2M. The obvious reading is that Ispire turned a corner on cash. It did not. The $20.7M credit loss is a non-cash charge, and it is the single largest add-back reconciling the loss to the cash flow. The loss did not shrink. It changed category: from cash going out the door to cash that was never going to come in.
2. Company Snapshot
Ispire designs and distributes vaping hardware. It sells nicotine e-cigarette products globally under the Aspire brand, and cannabis vaporizer hardware under the Ispire brand on an ODM basis to cannabis operators in the United States, Canada and South Africa. It manufactures some nicotine products in Malaysia on an OEM/ODM basis. It trades on Nasdaq, and its fiscal year ends June 30, so FY2026 is the year to June 30, 2026.
One correction worth making up front, because the ticker sits next to a lot of cannabis coverage: this is not primarily a cannabis company. Cannabis vaping products were $15.9M of $96.0M of revenue, 16.6%, down from 29.0% a year earlier. Tobacco vaping was $80.1M, 83.4%. Geographically, Europe is 63.9% of revenue and North America is 15.8%. The filing is also explicit that Ispire is not a plant-touching business: it states that it does "not 'touch the cannabis plant' in the production and sale of our hardware products and thus are not subject to the specific cannabis-related regulatory and taxation provisions of the industry (e.g., IRS Code Section 280E)." The 280E problem belongs to Ispire's customers, not to Ispire. Their inability to pay, however, belongs to both.
| FY2023 | FY2024 | FY2025 | FY2026 | |
|---|---|---|---|---|
| Revenue | $115.6M | $151.9M | $127.5M | $96.0M |
| Gross profit | $20.8M | $29.8M | $22.6M | $12.3M |
| Gross margin | 18.0% | 19.6% | 17.8% | 12.8% |
Revenue peaked in FY2024 and has fallen 36.8% since. The stock closed at $1.44 on September 15, 2026, a market capitalization of roughly $83M on the 57,754,471 shares the cover page reports outstanding as of September 14, 2026, inside a 52-week range of $1.01 to $3.87 (price and range: stockanalysis.com, quote timestamped September 15, 2026, 4:00 PM EDT).
3. The Financial Story
Start with the receivable, because everything else is downstream of it. The reported balance sheet shows accounts receivable falling from $39.6M to $19.8M and it is tempting to read that as collections. The filing's own schedule says otherwise.
| Accounts receivable | June 30, 2026 | June 30, 2025 |
|---|---|---|
| Gross | $46.0M | $64.9M |
| Allowance for credit losses | $(26.1)M | $(18.0)M |
| Net | $19.8M | $47.0M |
| of which current | $19.8M | $39.6M |
| of which non-current | none | $7.4M |
Total net receivable fell $27.1M, not $19.8M, because FY2025 carried a $7.4M non-current bucket that no longer exists. And 56.9% of the gross receivable is now reserved, up from 27.7%. Ispire believes it will not collect more than half of what its customers owe it.
The roll-forward shows how that happened:
| Allowance for credit losses | FY2026 | FY2025 |
|---|---|---|
| Opening balance | $18.0M | $5.9M |
| Provision for expected losses | $20.7M | $22.0M |
| Write-offs charged against the allowance | $(12.5)M | $(9.9)M |
| Closing balance | $26.1M | $18.0M |
$12.5M was written off outright in FY2026, after $9.9M in FY2025. The allowance has gone $5.9M to $18.0M to $26.1M in two years. On the cash flow statement, the change in accounts receivable contributed $6.4M of cash. That is the real collection number. The other roughly $12.5M of the gross decline left the balance sheet as a write-off, and the remaining gap is the reserve build. The receivable did not convert. It was mostly extinguished.
Now the cash flow reads correctly. The $33.2M net loss reconciles to a $569K operating outflow through roughly $31.6M of non-cash add-backs, of which the credit loss provision alone is $20.7M, about two thirds. Management's own MD&A describes it in plain terms, calling it an "add back of impairment of account receivable of $20.7 million." Strip that one line out and the picture is a company whose loss is overwhelmingly a write-down of what it is owed, not a drain of cash it is spending. The cash was already spent, in FY2024 and FY2025, when the inventory was bought and shipped. FY2026 is when Ispire admitted it is not coming back.
The revenue decline is deliberate, and that is the most encouraging fact in the filing. US product sales fell $17.4M, from $32.6M to $15.1M, a 53.6% collapse. The MD&A attributes it to "a tightening of our sales strategy which required higher upfront deposits and stricter payment terms, subsequently leading to a reduced participation from lower-tier accounts." Ispire cut its American revenue in half on purpose, by demanding money up front from customers who were not paying. That is the correct decision and it is expensive. A separate detail confirms the pressure: interest income rose to $343K "mainly due to increase in interest charged on late fees by North America." The company is now charging its customers late fees.
Europe fell too, by 17.1% to $61.4M, which the filing attributes to something different: "European regulatory uncertainties regarding disposable bans and flavor restrictions, which led distributors to adopt a cautious purchasing strategy." Two separate problems, one balance-sheet and one regulatory.
Gross margin fell from 17.8% to 12.8%, and the mix shift is why. Management names three causes: competitive pricing pressure, a $2.0M increase in inventory write-downs (from $0.8M to $2.8M), and the fact that "higher-margin cannabis vaping products sales decreased from 29.0% to 16.6% of total revenue." The cannabis line was the profitable one. Walking away from the customers who would not pay meant walking away from the margin.
The loss has a passport. The income tax note splits pretax income by jurisdiction, and it is the clearest table in the document:
| Pretax income (loss) | FY2026 | FY2025 |
|---|---|---|
| Hong Kong | $7.0M | $7.4M |
| United States | $(36.5)M | $(44.0)M |
| Malaysia | $(2.6)M | $(1.4)M |
| Consolidated | $(32.1)M | $(38.0)M |
The international nicotine business run out of Hong Kong made $7.0M of pretax profit for the second straight year. The American business lost $36.5M. Ispire is a profitable exporter attached to a loss-making US operation, and the consolidated loss is entirely the second thing.
Charged is not paid, and here it runs backwards from what you would expect. Ispire was charged $1.15M of income tax in FY2026 (us-gaap:IncomeTaxExpenseBenefit) while losing $32.1M pretax. Cash income taxes paid were $1.61M (us-gaap:IncomeTaxesPaid), more than the charge. US federal current and deferred tax were both nil. The reason is the jurisdictional split above: the profitable Hong Kong subsidiary owes real cash tax that the American losses cannot shelter, and the filing says the valuation allowance increased because management believes "the taxable income in the future will not be sufficient to utilize the carryforward loss."
Negative equity: what it does and does not mean. Shareholders' equity is negative $29.2M at June 30, 2026, having gone $34.5M (June 2024) to $0.6M (June 2025) to here. It means liabilities of $93.5M exceed assets of $64.3M. It is not by itself insolvency, it is not a default, and it does not mean the company stops trading.
What it does mean depends almost entirely on one counterparty. $76.3M of the $93.5M of total liabilities, 81.6%, is owed to Shenzhen Yi Jia, a Chinese company 95% owned by Ispire's Chairman and CEO, Tuanfang Liu (5% by his cousin). Mr. Liu also beneficially owns 57.6% of Ispire. Yi Jia is also the supplier: purchases from it were $72.1M in FY2026, 86% of the $83.7M cost of revenue, and one supplier accounts for 91% of total purchases in both years. Exclude the related-party balances and Ispire's equity is positive $47.1M.
The structure is load-bearing in a very specific way. Working capital at June 30, 2026 is positive $803K ($45.4M of current assets against $44.6M of current liabilities). It is positive only because $22.0M was reclassified out of current payables after Shenzhen Yi Jia agreed not to seek repayment for twelve months starting September 17, 2026 - two days after this 10-K was filed. Without that reclassification working capital is negative $21.2M. Yi Jia did the same thing a year earlier with $25.0M from September 30, 2025. The balances are non-interest bearing, unsecured, and the filing states there are "no fixed payment terms."
On going concern and covenants, report what is there. There is no going-concern qualification. Marcum Asia CPAs LLP issued a clean, unqualified opinion dated September 15, 2026, with no substantial-doubt paragraph and no critical audit matters section. The phrase "going concern" appears exactly once in the entire document, and it is about Ispire's customers: a risk factor warning that US cannabis operators' headwinds "may impair their ability to function as going concerns." There is no credit facility, no revolver and no financial covenants disclosed. Total bank borrowings are $805K, all current, down from $1.95M. Management states it "financed our operations primarily through cash on hand and working capital loans from our major stockholders, who are our chief executive officer and his wife," and believes current cash and operating cash flow "will be sufficient to meet our working capital needs in the next 12 months." Cash was $19.3M at year end, down from $24.4M.
One control finding belongs in the same paragraph as the allowance. Management concluded that disclosure controls and internal control over financial reporting were not effective at June 30, 2026, due to a material weakness in IT general controls. Separately, the FY2025 material weaknesses were remediated during FY2026, and one of them was precisely "the credit loss history and use of it to evaluate the sufficiency of credit loss reserve for accounts receivable under the Topic 326." Read that both ways: the FY2026 allowance is the first one built under controls management considers adequate for the estimate, which is a reason to trust the $26.1M more than the $18.0M, and it is also part of why the number moved.
4. Valuation: The Whole Question Is Whether $76.3M Is Debt
Conventional multiples do not work. There are no earnings, there is no EBITDA, book equity is negative, and free cash flow is negative. A projected DCF on a company with a $32.6M operating loss and no management forecast would be arithmetic dressed as analysis. The answerable question is narrower.
At $1.44, the market pays about $83M, which is 0.87 times revenue and 4.3 times the $19.3M of cash. Net of that cash, it pays roughly $64M for a group whose only profitable piece earns $7.0M of pretax income, about 9 times. That multiple is only sane if the $76.3M owed to the Chairman's company behaves like permanent capital rather than debt.
| Scenario | Stated assumptions | Implied equity | Per share |
|---|---|---|---|
| Bull | Related-party $76.3M keeps rolling; US losses stop; group earns the Hong Kong stream of ~$7.0M pretax, valued at 10x, plus $19.3M of cash | ~$89M | ~$1.55 |
| Base | Related-party rolls; the US takes two more years and ~$20M of cumulative loss to reach breakeven; capitalize $7.0M at 7x, plus cash, less that loss | ~$49M | ~$0.85 |
| Bear | The related-party balance is called, or the remaining $19.8M net receivable proves uncollectible: $93.5M of claims against $64.3M of assets | ~$0 | ~$0.00 |
Implied value under stated assumptions. Not a price target and not a recommendation. Every scenario holds the Hong Kong operation at its FY2026 pretax run rate and assumes no new equity issuance, which for a company with $19.3M of cash and no committed facility is a simplification.
Today's price sits nearer the bull case than the base case. What the market is pricing, then, is not a distressed asset. It is the assumption that the Chairman continues to fund his own company through his own supplier, and that the American losses stop. Both are plausible. Neither is contractual: the forbearance is twelve months at a time and the filing says there are no fixed payment terms.
5. Risks
The customer base and the supplier are both concentrations, and they sit on opposite sides of the same balance sheet. Two customers were 27% and 25% of FY2026 revenue, 52% between them. One customer is 32% of the total accounts receivable at June 30, 2026, up from 16% a year earlier, so the receivable is getting more concentrated while it is being written off. On the other side, one supplier is 91% of total purchases, and it is the Chairman's company. A dispute, a death, a change of control or a Chinese regulatory action touching Shenzhen Yi Jia would hit Ispire's cost of goods, its payables, its non-current liabilities and its working-capital classification at the same moment.
The rest is regulatory and structural. European disposable bans and flavor restrictions are already suppressing distributor orders in the 64% of revenue that Europe represents, and that pressure is outside management's control in a way the US credit tightening is not. US cannabis customers remain exposed to the economics the filing itself describes, where operators "may lead to insolvency or a takeover by creditors, as was the case recently with a major U.S. multistate cannabis operator." Nasdaq continued-listing requirements sit in the risk factors, though no deficiency notice is disclosed. Internal control over financial reporting is not effective. And the filing discloses just 16 holders of record with a public float of $53.6M at December 31, 2025, which is a thin, volatile security regardless of what the business does.
6. The Bottom Line
Ispire's FY2026 is a credit story that is being read as a cash story. The improvement in operating cash flow is real arithmetic and almost entirely the wrong signal: it happened because a $20.7M non-cash bad-debt charge sat inside a $33.2M loss. Underneath it, the company did the right unglamorous thing, cutting American revenue in half to stop shipping hardware to people who do not pay, at the cost of its highest-margin product line and five points of gross margin. The Hong Kong nicotine business is profitable and has been for two years. The negative equity is real but it is 82% a debt to the Chairman, rolled twelve months at a time, and the auditors signed a clean opinion.
Three things to watch in the fiscal Q1 2027 filing, due around mid-November 2026. First, the credit loss expense line: after two years above $20M, the thesis that the tightening worked requires it to fall sharply, and a third $20M year would say the new payment terms did not fix anything. Second, the allowance as a share of gross receivables, currently 56.9%, which tells you whether the remaining book is being cleaned or just aged. Third, US revenue at $15.1M, which needs to stabilize rather than keep falling, because the deliberate part of the decline should be finished.
Every figure above came out of Ispire Technology's FY2026 Form 10-K and its underlying XBRL, read directly from the filing through the RoboSystems SEC Shared Repository. Market price and 52-week range are attributed in the text.